GB2188843A - Buccal etorphine tablets - Google Patents
Buccal etorphine tablets Download PDFInfo
- Publication number
- GB2188843A GB2188843A GB08708587A GB8708587A GB2188843A GB 2188843 A GB2188843 A GB 2188843A GB 08708587 A GB08708587 A GB 08708587A GB 8708587 A GB8708587 A GB 8708587A GB 2188843 A GB2188843 A GB 2188843A
- Authority
- GB
- United Kingdom
- Prior art keywords
- etorphine
- buccal tablet
- buccal
- tablets
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 title claims description 11
- 229950004155 etorphine Drugs 0.000 title claims description 11
- 239000006189 buccal tablet Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 229940046011 buccal tablet Drugs 0.000 claims description 7
- 229920000161 Locust bean gum Polymers 0.000 claims description 6
- 239000000711 locust bean gum Substances 0.000 claims description 6
- 235000010420 locust bean gum Nutrition 0.000 claims description 6
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 3
- 240000008886 Ceratonia siliqua Species 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000003071 maltose group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- CAHCBJPUTCKATP-UHFFFAOYSA-N 4,5-epoxy-3-hydroxy-6-methoxy-α,17-dimethyl-α-propyl-[5α,7α(r)]-6,14-ethenomorphinan-7-methanol Chemical compound CCCC(C)(O)C1CC23C=CC1(OC)C1OC4=C5C31CCN(C)C2CC5=CC=C4O CAHCBJPUTCKATP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000005178 buccal mucosa Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JNHPUZURWFYYHW-DTUSRQQPSA-N (1R,2S,6R,14R,15R,19R)-19-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol hydrochloride Chemical compound Cl.O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O JNHPUZURWFYYHW-DTUSRQQPSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Description
1 GB 2 188 843 A 1
SPECIFICATION
Pharmaceutical compositions This invention relates to pharmaceutical compositions and in particularto compositions containing etorph- 5 ine.
Etorphine (IN N for 7,et-1 -(S)-hydroxy-1 -methyl butyl-6,14-endoethen o6,7,8,14-tetra hyd ro-o ri pavi n e) in the form of the free base or its salts is a potent analgesic in both animals and man. Upon intramuscular adminis tration to patients with a difficult pain control problem analgesia has been observed within 2-3 minutes of injection and has persisted for 1.5-2 hours. The majority of these patients were given etorphine in the dose range 50-400 ug which was judged to provide greater benefit relative to other analgesics. Studies in dog have shown etorphine to be more effective than morphine after sublingual administration. In patients sublingual etorphine was found to be beneficial with onset of effect occurring less than 10 minutes after tabletdissolu tion with the analgesic effect lasting for 1.5 to 4 hours.
Experiments in animals have shown that etorphine passes rapidly across the buccal mucosa and into the 15 systemic circulation. We have now developed a buccal tabletthat controls the release of the drug andthereby slows down the rate of absorption into the buccal tissue and thus increases the duration of analgesia.
According to this invention there is provided a buccal tablet comprising etorphine or a saitthereof, at least one monosaccharide, disaccharide or a mixture thereof, and a mixture of xanthan gum and locust bean gum in a weight ratio of 3:1 to 1: 1, wherein the total weight of the mono- andlor di-saccharides relative to the combined weight of the xanthan and locust bean gums is in the ratio of 20:1 to 3:1 and preferably in the ratio of 12:1 to 5: 1.
Suitable monosaccharides include glucose, galactose, fructose, mannose, mannitol and sorbitol. The dis- accharides include maltose, lactose and sucrose, a preferred carrier being sucrose.
The tablets will normally contain 50 to 200 jig etorphine hydrochloride and conveniently 100 [Lg.
The locust bean gum is preferably a cold-water dispersible type such as Meyprodyn 200 (Registered Trade Mark, Meyhall Chemical A.G. Switzerland).
Thetabletswill preferably contain binding agents such as polyvinyl pyrrolidone, lubricating agents such as magnesium stearate and/or glidants such astalc.
The tablets are prepared by standard tabletting procedures in which various components are blended 30 together and the mixture directly compressed or else there is a pregranulation stage using forexample awet granulation with aqueous ethanol or isopropanol followed bythetabletting.
The buccal tablets of the present invention are placed between the gingival surface of thejaw andthe buccal mucosa where they gel bywater absorption to produce a soft hydrated tabletwhich maybe retained in position giving prolonged and controlled release of the drug by diffusion for up to two hours.
The invention is illustrated by the following Examples:
Examples 1-3
Buccal tablets (60 mg) were prepared having thefollowing compositions:
40 mg Xanthan Gum (Keltrol F) X Locust Bean Gum (Meyprodyn 200) y Etorphine HCI 0.10 45 Polyvinyl pyrrolidone (Kollidon K30 BASF) 1.20 Sucrose (MicrotaHD.C.D. Tate and Lyle) 57.20-(x+y) Talc 1.0 Magnesium Stearate 0.50 50 wherex and y are respectively:
Example 1 2 3 x= 1.5 2.5 2.25 1.5 2.5 0.75 Y= The tablets were prepared by blending together the xa nthan gum, locust bean g u m, polyvinyl pyrrolidone, and sucrose. The mixed powders were then wet granulated using an 8:5 (v/v) ethanol:water mixture, con- taining the dissolved etorphine HCI, by hand using a mortar and pestle. The damp granules were dried at 45'C. After drying the mass was passed through a 500 Km sieve, blended with the tale and magnesium stearate and compressed into 5.56 mm diameter normal concave tablets of nominal weight 60 mg and breaking strength 2-5 kp using a single punch tablet press.
2 GB 2 188 843 A - 2 Examples 4-6
Buccal tablets (60 mg) were prepared, having the composition of Examples 1-3, but also including the colouring agent erythrosine (6 [Lg) added to the 8:5 ethanol:water granulating fluid.
Examples 7-9
Buccal tablets (80 mg) were prepared having the composition:
mg Xanthan Gum (Keltrol F) X 10 Locust Bean Gum (Meyprodyn 200) y Etorphine HCI 0.10 Polyvinylpyrrolidone Wollidon 30 BASF) 1.6 Sucrose 76.30-(x+y) Talc 1.3 15 Magnesium Stearate 0.7 wherex and V are respectively:
Example 7 8 9 5 6 7 5 6 7 X= Y= The granules bulk mixeswere prepared as in Examples 13 and the tablets of nominal weight 80 mg and 25 6.35 mm normal concave profile were compressed on a single punch tablet press.
Examples 10-12 Buccal tablets (80 mg) were prepared, having the composition of Examples 7-9, but also including the colouring agent erythrosine (20 jig) added to the 8:5 ethanol:water granulating fluid.
Examples 13-15 Buccal tablets (80 mg) similarto those of Examples 7-9 were prepared using lactose 13.P. in the place ofthe sucrose.
Examples 16-18 Buccaltablets (80 mg) similar to those of Examples7-9were prepared using mannitol inthe placeofthe sucrose.
Examples 19-21 Buccaltablets (80 mg) similar to those of Exam pies 7-9 were prepared using anhydrous dextrose B.P. inthe place of the sucrose.
Examples22-24
Buccal tablets (80 mg) similarto those of Examples 7-9 were prepared using fructose in the place of the 45 sucrose.
Examples25-27
Buccal tablets (80 mg) similarto those of Examples 7-9 were prepared using sorbitol in the place of the sucrose.
The in-vitro release rate of the buccal tablets was investigated using a method based on British Pharmac opoeia 1980, Volume li, Al 14. Tablets were placed in a standard wire gauze basket (Copley Instruments (Nottingham) Limited) and rotated at 100 rpm in 100 mi of 0.1 M phosphate buffer (pH 6.7) contained in a 150 mi tall form beaker, placed in a water bath maintained at 37:L YC. At intervals 200 jil aliquots were removed and replaced by 200 1A buffer. The sample solutions (50 L1) were assayed for etorphine content by high performance liquid chromatography using 1 % aqueous ammonium acetate: methanol (40:60) as the mobile phase delivered at 2 mi/min (by a Kontrol 420 pump) through a 10 cm X 0. 46 cm id stainless steel column packed with Hypersil 5 Rm ODS packing material. Etorphine contentwas monitored by electrochemical detection using a BAS LC4-B detector at a potential of +0.75 volts (O. 5nAf.s.d.). Quantitation was carried out automatically using a Hewlett-Packard 3390 or3393 computing integrator.
The Table presents data of in-vitro dissolution of Examples land 2.
T k C.
3 GB 2 188 843 A 3 Table
Time % released Hours Examplel Example2 5 0 0 0 0.5 41.2 24.3 1 76.3 57.2 2 97.1 71.9 3 83.4 10 From the results it can be seen that the rate of drug release decreases with increasing xanthan and locust bean gum content.
Tables containing xanthan/Meyprodyn gum mixtures gel in the mouth bywater absorption to give a soft tabletwhich adheres to the buccal mucosa and subsequently remains in position for upto two hours.
Comparative tablets containing none of the gum mixture do not gel, buttend to remain in position asthe tabletwets, howeverwhen fully hydrated the tablet disintegratesto hard course particlesthat have no adhesive properties. Such tablets have undesirable organoleptic properties and their inherent inabilityto adhereto the mucosa makesthem less likelyto give satisfactory buccal absorption and makes then less acceptable than the soft buccal tablets of this invention.
Claims (6)
1. A buccal tablet comprising etorphine or a salt thereof, at least one monosaccharide, disaccharide or a mixture thereof, and a mixture of xanthan gum and locust bean gum in a weight ratio 3:1 to 1: 1, wherein the 25 total weight of the mono- and/or di-saccharides relative to the combined weight of the xanthan and locus bean gums is in the ratio of 20:1 to 3: 1.
2. A buccal tablet as claimed in claim 1 wherein the total weight of the mono- and/or di-saccharides relative to the combined weight of the xanthan and locust bean gums is in the ratio of 12:1 to 5: 1.
3. A buccal tablet as claimed in claim 1 or claim 2 wherein the weight of etorphine is between 50 and 200 Kg.
4. A buccal tablet as claimed in claim 1, claim 2 or claim 3 wherein the monosaccharide is glucose, galactose, fructose, mannose, mannitol orsorbitol.
5. A buccal tablet as claimed in claim 1, claim 2 or claim 3 wherein the disaccharide is maltose, lactose or sucrose.
6. A buccal tablet as claimed in claim 1 substantially as hereinbefore described with referenceto anyone of Examples 1 to 27.
Printed for Her Majesty's Stationery Office by Croydon Printing Company (U K) Ltd,8187, D8991685. Published by The Patent Office, 25 Southampton Buildings, London WC2A l AY, from which copies maybe obtained.
A 1 4
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868608818A GB8608818D0 (en) | 1986-04-11 | 1986-04-11 | Pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8708587D0 GB8708587D0 (en) | 1987-05-13 |
| GB2188843A true GB2188843A (en) | 1987-10-14 |
| GB2188843B GB2188843B (en) | 1990-04-11 |
Family
ID=10596029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB868608818A Pending GB8608818D0 (en) | 1986-04-11 | 1986-04-11 | Pharmaceutical compositions |
| GB8708587A Expired - Lifetime GB2188843B (en) | 1986-04-11 | 1987-04-10 | Buccal etorphine tablets. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB868608818A Pending GB8608818D0 (en) | 1986-04-11 | 1986-04-11 | Pharmaceutical compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4829056A (en) |
| EP (1) | EP0245952A3 (en) |
| AU (1) | AU7141087A (en) |
| DK (1) | DK184087A (en) |
| GB (2) | GB8608818D0 (en) |
| PT (1) | PT84662B (en) |
| ZA (1) | ZA872520B (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0371466A1 (en) * | 1988-11-30 | 1990-06-06 | Schering Corporation | Fast buccal tablet |
| EP0360562A3 (en) * | 1988-09-19 | 1990-11-22 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| FR2649611A1 (en) * | 1989-07-13 | 1991-01-18 | Philippe Perovitch | Process for preparing a dosage form of a therapeutic composition, in particular one based on aspirin |
| US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| WO1994006426A1 (en) * | 1992-09-21 | 1994-03-31 | Qin Bo Yi | Methods for identifying and using low/non-addictive opioid analgesics |
| US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5624932A (en) * | 1992-09-21 | 1997-04-29 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
| US5683721A (en) * | 1990-07-26 | 1997-11-04 | Perovitch; Philippe | Galenic preparation of therapeutic composition comprising aspirin |
| US6039980A (en) * | 1996-01-29 | 2000-03-21 | Edward Mendell Co., Inc. | Sustained release excipient |
| FR2972327A1 (en) * | 2011-03-11 | 2012-09-14 | Le Stum Lab | Oral nutraceutical composition, useful for preventing and/or treating glutathione deficiencies, comprises combination of antioxidants comprising glutathione and hydrolyzable tannin and mucoadhesive and matrix vehicle and regulating agent |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
| PH26730A (en) * | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
| US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| IL123505A (en) * | 1996-07-08 | 2004-12-15 | Penwest Pharmaceuticals Compan | Sustained release matrix for high-dose insoluble drugs |
| US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
| IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| US6319510B1 (en) | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| GB0320854D0 (en) | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
| US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR893228A (en) * | 1941-07-03 | 1944-06-02 | Ste Ind Chim Bale | Method of manufacturing vehicles which can be used with active substances |
| US2407486A (en) * | 1941-11-21 | 1946-09-10 | Du Pont | Veterinary compositions |
| GB981372A (en) * | 1960-05-04 | 1965-01-27 | Pfizer Ltd | Pharmaceutical formulations for oral administration to animals |
| US3218232A (en) * | 1962-11-09 | 1965-11-16 | American Home Prod | Method for relieving depression and composition therefor |
| US3557016A (en) * | 1965-10-22 | 1971-01-19 | Kelco Co | Heat reversible gel and method for preparing same |
| US4076804A (en) * | 1975-07-18 | 1978-02-28 | Abbott Laboratories | Erythromycin therapy |
| US4038206A (en) * | 1976-01-15 | 1977-07-26 | General Mills Chemicals, Inc. | Hydroxyalkyl locust bean/xanthomonas hydrophilic colloid blends |
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| GB1604850A (en) * | 1977-11-24 | 1981-12-16 | Wellcome Found | Biologically active peptides |
| GB1604644A (en) * | 1977-07-22 | 1981-12-09 | Wellcome Found | Biologically active pentapeptide amides |
| US4315936A (en) * | 1979-12-17 | 1982-02-16 | Ortho Pharmaceutical Corporation | Analgesic composition |
| JPS58210007A (en) * | 1982-06-02 | 1983-12-07 | Takeda Chem Ind Ltd | Oral preparation for giving to upper buccogingival transition |
| CA1208558A (en) * | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4598087A (en) * | 1983-12-06 | 1986-07-01 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US4599342A (en) * | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
| GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| US4559326A (en) * | 1985-01-31 | 1985-12-17 | Pfizer Inc. | Antiinflammatory compositions and methods |
| GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
-
1986
- 1986-04-11 GB GB868608818A patent/GB8608818D0/en active Pending
-
1987
- 1987-04-08 ZA ZA872520A patent/ZA872520B/en unknown
- 1987-04-09 EP EP87303121A patent/EP0245952A3/en not_active Withdrawn
- 1987-04-10 US US07/037,191 patent/US4829056A/en not_active Expired - Fee Related
- 1987-04-10 GB GB8708587A patent/GB2188843B/en not_active Expired - Lifetime
- 1987-04-10 PT PT84662A patent/PT84662B/en unknown
- 1987-04-10 AU AU71410/87A patent/AU7141087A/en not_active Abandoned
- 1987-04-10 DK DK184087A patent/DK184087A/en not_active Application Discontinuation
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0360562A3 (en) * | 1988-09-19 | 1990-11-22 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
| US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| WO1990006136A1 (en) * | 1988-11-30 | 1990-06-14 | Schering Corporation | Fast buccal tablet |
| EP0371466A1 (en) * | 1988-11-30 | 1990-06-06 | Schering Corporation | Fast buccal tablet |
| US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| FR2649611A1 (en) * | 1989-07-13 | 1991-01-18 | Philippe Perovitch | Process for preparing a dosage form of a therapeutic composition, in particular one based on aspirin |
| WO1992001444A1 (en) * | 1989-07-13 | 1992-02-06 | Philippe Perovitch | Galenical preparation method for preparing a therapeutical composition particularly based on aspirin |
| EP0468121A1 (en) * | 1989-07-13 | 1992-01-29 | Philippe Perovitch | Process for the galenical preparation of a therapeutic composition, in particular based on aspirin |
| US5629022A (en) * | 1989-07-13 | 1997-05-13 | Perovitch; Philippe | Method for galenically preparing a therapeutic composition based on aspirin |
| US5683721A (en) * | 1990-07-26 | 1997-11-04 | Perovitch; Philippe | Galenic preparation of therapeutic composition comprising aspirin |
| US5670168A (en) * | 1992-07-30 | 1997-09-23 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5478574A (en) * | 1992-07-30 | 1995-12-26 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| WO1994006426A1 (en) * | 1992-09-21 | 1994-03-31 | Qin Bo Yi | Methods for identifying and using low/non-addictive opioid analgesics |
| US5633259A (en) * | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
| US5624932A (en) * | 1992-09-21 | 1997-04-29 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
| US6039980A (en) * | 1996-01-29 | 2000-03-21 | Edward Mendell Co., Inc. | Sustained release excipient |
| FR2972327A1 (en) * | 2011-03-11 | 2012-09-14 | Le Stum Lab | Oral nutraceutical composition, useful for preventing and/or treating glutathione deficiencies, comprises combination of antioxidants comprising glutathione and hydrolyzable tannin and mucoadhesive and matrix vehicle and regulating agent |
Also Published As
| Publication number | Publication date |
|---|---|
| DK184087D0 (en) | 1987-04-10 |
| DK184087A (en) | 1987-10-12 |
| PT84662B (en) | 1989-05-29 |
| GB8608818D0 (en) | 1986-05-14 |
| GB2188843B (en) | 1990-04-11 |
| PT84662A (en) | 1987-05-01 |
| GB8708587D0 (en) | 1987-05-13 |
| EP0245952A2 (en) | 1987-11-19 |
| AU7141087A (en) | 1987-10-15 |
| EP0245952A3 (en) | 1988-02-10 |
| ZA872520B (en) | 1987-11-25 |
| US4829056A (en) | 1989-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2188843A (en) | Buccal etorphine tablets | |
| DE60107641T2 (en) | Transdermal therapeutic system | |
| CA1201064A (en) | Constant release rate solid oral dosage formulations of drugs having a pk.sub.a7-10 and an aqueous solubility of 15-100 g/ml water | |
| US5672356A (en) | Bioadhesive pharmaceutical composition for the controlled release of active principles | |
| US4910023A (en) | Drug in combination with flavor masking agent and method for making same | |
| CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
| US20150037417A1 (en) | Morphine polymer release system | |
| EP0279976A1 (en) | Pseudoephedrine dosage form | |
| AU8052487A (en) | Controlled release hydromorphone composition | |
| HU226375B1 (en) | Once-day metoprolol tablet | |
| US6806294B2 (en) | Opioid analgesic | |
| SE453797B (en) | THERAPEUTIC, SOLID UNIT DOSAGE FORM WITH EXTENDED DISPOSAL SAMPLES WHERE BERARM MATERIALS INCLUDE HYDROXYPROPYLMETHYL CELLULOSA WITH HIGH MOLECULES WEIGHT | |
| NO930743L (en) | MINI-CYCLE PULSE PULSING DAYS | |
| CA2253980A1 (en) | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof | |
| GB9303133D0 (en) | Spheroid formulation | |
| US3865935A (en) | Tableting of erythromycin base | |
| WO2007146006A2 (en) | Sustained release oxycodone composition with acrylic polymer and a surfactant | |
| EP0181650B1 (en) | Compression-coated dispersible tablets | |
| US4738850A (en) | Controlled release formulation and method | |
| EP2005946A1 (en) | Method for producing extended release tablet | |
| WO2007146005A2 (en) | Sustained release oxycodone composition with acrylic polymer and metal hydroxide | |
| KR970701047A (en) | ANTITUSSIVE COMPOSITION CONTAINING AN ANTITUS SIVE AND BENZYDAMINE | |
| US4454142A (en) | Hyperkinetic child treatment agent | |
| JPS6314715A (en) | Sustained release formulation composition | |
| CA1334933C (en) | Pharmaceutical composition and process for its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |